108552
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
中药在低氧性肺动脉高压治疗中的作用：机制、进展与未来方向
Authors Wang X, Deng T, Zhu H , Peng J, Liang J, Zhong S, Yao C, Jin G
Received 3 April 2025
Accepted for publication 28 August 2025
Published 15 September 2025 Volume 2025:19 Pages 8265—8294
DOI https://doi.org/10.2147/DDDT.S531109
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Mariana Carmen Chifiriuc
Xunkai Wang,1– 3,* Tang Deng,1,4,* Houfan Zhu,1– 3,* Jin Peng,1– 3 Jinxi Liang,5 Shijie Zhong,1– 3 Chen Yao,4 Guiyun Jin1– 3
1Department of Interventional Radiology and Vascular Surgery, The First Affiliated Hospital, Hainan Medical University, Haikou, People’s Republic of China; 2Department of Emergency, The First Affiliated Hospital, Hainan Medical University, Haikou, People’s Republic of China; 3Key Laboratory of Emergency and Trauma Ministry of Education, College of Emergency and Trauma, Hainan Medical University, Haikou, People’s Republic of China; 4Division of Vascular Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China; 5Department of Ophthalmology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Chen Yao, Division of Vascular Surgery, The First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Yuexiu District, Guangzhou, Guangdong, People’s Republic of China, Tel +8613501504763, Email yaochen@mail.sysu.edu.cn Guiyun Jin, Department of Interventional Radiology and Vascular Surgery, The First Affiliated Hospital, Hainan Medical University, No. 31, Longhua Road, Longhua District, Haikou, Hainan, People’s Republic of China, Tel +8613976609625, Email 13976609625@163.com
Abstract: Hypoxic pulmonary hypertension (HPH) is a severe subtype of pulmonary hypertension(PH) characterized by chronic lung disease or prolonged hypoxia, leading to pulmonary vascular remodeling and right heart failure. Traditional Chinese Medicine (TCM) has garnered significant attention for its potential therapeutic effects on HPH due to its minimal side effects, multiple target actions, affordability, and cultural acceptance. Recent studies have highlighted the potential of TCM in inhibiting pulmonary artery smooth muscle cell proliferation, modulating inflammation, and oxidative stress. This review aims to explore the mechanisms of action of TCM in treating HPH, focusing on its ability to modulate key signaling pathways involved in pulmonary vascular remodeling, such as PI3K/Akt, Nrf2, NF-κB, and RhoA/ROCK. The goal is to provide a comprehensive overview of the current progress and future directions in the application of TCM for HPH treatment. TCM demonstrates significant therapeutic potential in HPH by modulating signaling pathways involved in inflammation, oxidative stress, and pulmonary vascular remodeling. Key compounds such as taxifolin glycoside, resveratrol, and salidroside have shown promising effects in inhibiting abnormal proliferation of pulmonary artery smooth muscle cells (PASMCs) and reducing oxidative stress. These mechanisms contribute to the overall efficacy of TCM in preventing and treating HPH. By modulating key signaling pathways and exerting anti-inflammatory and antioxidant effects, TCM offers a promising therapeutic approach for HPH. Further research is needed to validate the clinical efficacy and safety of TCM formulations, and to explore the underlying mechanisms through modern scientific methods. The integration of TCM with modern medicine could provide new strategies for the treatment of HPH.
Keywords: hypoxic pulmonary hypertension, Chinese herbal medicine, antioxidant, mechanisms, vascular remodeling, signaling pathway
1Department of Interventional Radiology and Vascular Surgery, The First Affiliated Hospital, Hainan Medical University, Haikou, People’s Republic of China; 2Department of Emergency, The First Affiliated Hospital, Hainan Medical University, Haikou, People’s Republic of China; 3Key Laboratory of Emergency and Trauma Ministry of Education, College of Emergency and Trauma, Hainan Medical University, Haikou, People’s Republic of China; 4Division of Vascular Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China; 5Department of Ophthalmology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Chen Yao, Division of Vascular Surgery, The First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Yuexiu District, Guangzhou, Guangdong, People’s Republic of China, Tel +8613501504763, Email yaochen@mail.sysu.edu.cn Guiyun Jin, Department of Interventional Radiology and Vascular Surgery, The First Affiliated Hospital, Hainan Medical University, No. 31, Longhua Road, Longhua District, Haikou, Hainan, People’s Republic of China, Tel +8613976609625, Email 13976609625@163.com
Abstract: Hypoxic pulmonary hypertension (HPH) is a severe subtype of pulmonary hypertension(PH) characterized by chronic lung disease or prolonged hypoxia, leading to pulmonary vascular remodeling and right heart failure. Traditional Chinese Medicine (TCM) has garnered significant attention for its potential therapeutic effects on HPH due to its minimal side effects, multiple target actions, affordability, and cultural acceptance. Recent studies have highlighted the potential of TCM in inhibiting pulmonary artery smooth muscle cell proliferation, modulating inflammation, and oxidative stress. This review aims to explore the mechanisms of action of TCM in treating HPH, focusing on its ability to modulate key signaling pathways involved in pulmonary vascular remodeling, such as PI3K/Akt, Nrf2, NF-κB, and RhoA/ROCK. The goal is to provide a comprehensive overview of the current progress and future directions in the application of TCM for HPH treatment. TCM demonstrates significant therapeutic potential in HPH by modulating signaling pathways involved in inflammation, oxidative stress, and pulmonary vascular remodeling. Key compounds such as taxifolin glycoside, resveratrol, and salidroside have shown promising effects in inhibiting abnormal proliferation of pulmonary artery smooth muscle cells (PASMCs) and reducing oxidative stress. These mechanisms contribute to the overall efficacy of TCM in preventing and treating HPH. By modulating key signaling pathways and exerting anti-inflammatory and antioxidant effects, TCM offers a promising therapeutic approach for HPH. Further research is needed to validate the clinical efficacy and safety of TCM formulations, and to explore the underlying mechanisms through modern scientific methods. The integration of TCM with modern medicine could provide new strategies for the treatment of HPH.
Keywords: hypoxic pulmonary hypertension, Chinese herbal medicine, antioxidant, mechanisms, vascular remodeling, signaling pathway